Preparation and identification of scFv and bsFv against transferrin receptor

Abstract

To obtain single chain variable fragment (scFv) and bivalent single chain variable fragment (bsFv) against transferrin receptor, up-stream and down-stream primers were designed according to the complementary sequences of FR1 region of variable heavy (VH) and FR4 of variable light (VL), respectively, which contained inter-linker G4S and the restriction endonuclease SfiI, AscI and NotI. Two pieces of scFv fragments were first amplified through PCR and then inserted into plasmid pAB1, which could express scFv protein once induced by IPTG in the host bacteria. To express scFv and bsFv, E. coli TG1 was cultured in LB broth and was induced by IPTG. The restriction enzyme digestion map and DNA sequencing demonstrated that scFv and bsFv genes were successfully inserted into the expression plasmid. SDS-PAGE and Western blotting revealed the protein band at 35kD and 60kD, which were consistent with the molecular weight of scFv and bsFv respectively. Flow cytometry showed that scFv and bsFv harbored the specific binding activity with TfR expressed in various tumor cells, and the avidity of bsFv was higher than that of the parent scFv.

Keywords

gene sequence / G4S linker / scFv / bsFv / transferrin receptor

References

[1] DanielsT. R., DelgadoT., RodriguezJ. A., et al.. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol, 2006, 121(2): 144-158

[2] QingY., ShuoW., ZhihuaW., et al.. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother, 2006, 55(9): 1111-1121

[3] LeiP., HeY., YeQ., et al.. Antigen-binding characteristics of AbCD71 and its inhibitory effect on PHA-induced lymphoproliferation. Acta Pharmacol Sin, 2007, 28(10): 1659-1664

[4] BiècheI., OliviM., ChampèmeM. H., et al.. Novel approach to quantitative polymerase chain reaction using real time detection:application to the detection of gene amplification in breast cancer. Int J Cancer, 1998, 78(5): 661-666

[5] KohgoY., KondoH., MogiY., et al.. Mechanism and clinical significance of soluble hepatic cell-surface receptors. Targeted Diagn Ther, 1991, 4: 305-319

[6] WideraA., NorouziyanF., ShenW. C.. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev, 2003, 55(11): 1439-1466

[7] KolliaP., SamaraM., StamatopoulosK., et al.. Molecular evidence for transferrin receptor 2 expression in all FAB subtypes of acutemyeloid leukemia. Leuk Res, 2003, 27(12): 1101-1103

[8] YangD. C., WangF., ElliottR. L., et al.. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anticancer Res, 2001, 21(1B): 541-549

[9] TakuboT., KumuraT., NakaoT., et al.. Clinical usefulness of combined measurements of serum soluble transferrin receptor levels and serum interleukin-18 levels at determination of serum KL-6 levels in haematologic malignancies. Acta Haematol, 2000, 104(2–3): 141-143

[10] DanielsT. R., DelgadoT., HelgueraG., et al.. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol, 2006, 121(2): 159-176

[11] PirolloK. F., DagataJ., WangP., et al.. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging, 2006, 5(1): 41-52

[12] AsaiT., TrinhR., PenichetM. L., et al.. A human bioti acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng, 2005, 21(6): 145-155

[13] RodríguezJ. A., HelgueraG., DanielsT. R.. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J Control Release, 2007, 124(1–2): 35-42

[14] HsuC. P., KoJ. L., ShaiS. E., et al.. Modulation of telomere shelterin by TFR1 and TRF2 interacts with telomerase to maintain the telomere length in non-small cell lung cancer. Lung Cancer, 2007, 58(3): 310-316

[15] Högemann-SavellanoD., BosE., BlondetC., et al.. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia, 2003, 5(6): 495-506

[16] ShinoharaH., FanD., OzawaS., et al.. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by an titransferrin recombinant immunotoxin. Int J Oncol, 2000, 17(4): 643-651

[17] BhatiaJ., SharmaS. K., ChesterK. A., et al.. Catalytic activit of an in vivo tumor targeted anti-CEA scFv: carboxypeptidase G2 fusion protein. Int J Cancer, 2000, 85(4): 571-576

[18] KurokiM., ArakawaF., KhareP. D. e. a1.. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Anticancer Res, 2000, 20(6A): 4067-4071

[19] YangD. F., ZhuH. F., ShenG. X., et al.. Construction of single chain fv antibody against transferrin receptor and its protein fusion with alkaline phosphatase. World J Gastroenterol, 2005, 11(21): 3300-3304

[20] PengJ. L., WuS., ZhaoX. P., et al.. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem Bioph Res Co, 2007, 354(4): 864-871